Top Markets
Coin of the day
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Kedudukan dalam Saham #25523
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Harga Saham
$9.81
Disegerakkan terakhir: 2025-03-18
Modal Pasaran
$48.68M
Perubahan (1 hari)
1.55%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan AlloVir, Inc. (ALVR)

Kategori

Sejarah harga saham bagi AlloVir, Inc. (ALVR)
Harga penutupan tertinggi: $9.65 pada 2025-03-01

Harga penutupan terendah: $578.34 pada 2020-07-01
Sejarah harga saham AlloVir, Inc. dari 2020 hingga 2026
Prestasi harga saham tahunan
Tahun Prestasi
2025 -11.26%
2024 -74.50%
2023 -70.35%
2022 -60.21%
2021 -61.81%
2020 0.00%
Harga saham bagi syarikat atau pesaing serupa
Syarikat Harga saham Perubahan 1thn% Negara
$539.14 35.65%
US
$1.04K 56.21%
NL
$118.33 -18.49%
AU
$761.87 8.65%
CH
$130.43 397.46%
US